Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Impact of body mass index on surgical outcomes of gastric cancer

Authors: Fan Feng, Gaozan Zheng, Xiaohua Guo, Zhen Liu, Guanghui Xu, Fei Wang, Qiao Wang, Man Guo, Xiao Lian, Hongwei Zhang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

The association between body mass index (BMI) and clinical outcomes of gastric cancer were still under debate. The aim of the present study was to investigate the impact of BMI on intraoperative conditions, postoperative complications and prognosis of gastric cancer.

Methods

From October 2008 to March 2015, 1210 gastric cancer patients treated with D2 gastrectomy were enrolled in the present study. Patients were divided into three groups: low BMI group (BMI < 18.5 Kg/m2), normal BMI group (18.5 Kg/m2 ≤ BMI < 25.0 Kg/m2) and high BMI group (BMI ≥ 25.0 Kg/m2). Clinicopathological characteristics and prognosis of patients were recorded and analyzed. Propensity score matching was used to match patients in the three groups.

Results

There were 107 patients in low BMI group (8.9%), 862 patients in normal BMI group (71.2%) and 241 patients in high BMI group (19.95%). Before matching, BMI was inversely associated with tumor size, tumor depth, lymph node metastasis (LNM) and tumor stage (all P < 0.05). After matching, the clinicopathological features were all comparable among the three groups (all P > 0.05). High BMI was associated with increased blood loss and operation time, and deceased number of retrieved lymph nodes (all P < 0.05). For postoperative complications, low BMI was associated with decreased rate of postoperative fever (P = 0.025). Age, BMI, tumor size, Borrmann type, pathological type, type of gastrectomy, tumor depth, LNM and tumor stage were risk factors for the prognosis of gastric cancer. Multivariate analysis showed that only BMI, tumor size, tumor depth and LNM were independent prognostic factors. The overall survival of patients with low BMI was significantly worse than patients with normal (P < 0.05) or high BMI (P < 0.05). However, the overall survival was comparable between patients with normal and high BMI (P > 0.05).

Conclusions

BMI was inversely associated with tumor size, tumor depth, LNM and tumor stage. High BMI was associated with increased blood loss and operation time, and deceased number of retrieved lymph nodes. Low BMI was associated with decreased rate of postoperative fever and decreased survival.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
3.
Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, De Luca R, Petrioli R, Martinotti M, Generali D, et al. Surgical management of advanced gastric cancer: an evolving issue. Eur J Surg Oncol. 2016;42(1):18–27.CrossRefPubMed
4.
Kim JM, Park JH, Jeong SH, Lee YJ, Ju YT, Jeong CY, Jung EJ, Hong SC, Choi SK, Ha WS. Relationship between low body mass index and morbidity after gastrectomy for gastric cancer. Ann Surg Treat Res. 2016;90(4):207–12.CrossRefPubMedPubMedCentral
5.
Liedman B, Andersson H, Berglund B, Bosaeus I, Hugosson I, Olbe L, Lundell L. Food intake after gastrectomy for gastric carcinoma: the role of a gastric reservoir. Br J Surg. 1996;83(8):1138–43.CrossRefPubMed
6.
Alipour S, Kennecke HF, Woods R, Lim HJ, Speers C, Brown CJ, Gill S, Renouf DJ, Cheung WY. Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer. J Gastrointest Cancer. 2013;44(2):203–10.CrossRefPubMed
7.
Blom RL, Lagarde SM, Klinkenbijl JH, Busch OR, van Berge Henegouwen MI. A high body mass index in esophageal cancer patients does not influence postoperative outcome or long-term survival. Ann Surg Oncol. 2012;19(3):766–71.CrossRefPubMed
8.
Bao PP, Cai H, Peng P, Gu K, Su Y, Shu XO, Zheng Y. Body mass index and weight change in relation to triple-negative breast cancer survival. Cancer Causes Control. 2016;27(2):229–36.CrossRefPubMed
9.
Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on eastern cooperative oncology group clinical trials. J Thorac Oncol. 2013;8(9):1121–7.CrossRefPubMedPubMedCentral
10.
Bickenbach KA, Denton B, Gonen M, Brennan MF, Coit DG, Strong VE. Impact of obesity on perioperative complications and long-term survival of patients with gastric cancer. Ann Surg Oncol. 2013;20(3):780–7.CrossRefPubMed
11.
Chen HN, Chen XZ, Zhang WH, Yang K, Chen XL, Zhang B, Chen ZX, Chen JP, Zhou ZG, Hu JK. The impact of body mass index on the surgical outcomes of patients with gastric cancer: a 10-year, single-institution cohort study. Medicine (Baltimore). 2015;94(42):e1769.CrossRef
12.
Ejaz A, Spolverato G, Kim Y, Poultsides GA, Fields RC, Bloomston M, Cho CS, Votanopoulos K, Maithel SK, Pawlik TM. Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. J Surg Res. 2015;195(1):74–82.CrossRefPubMed
13.
Voglino C, Di Mare G, Ferrara F, De Franco L, Roviello F, Marrelli D. Clinical and oncological value of preoperative BMI in gastric cancer patients: a single center experience. Gastroenterol Res Pract. 2015;2015:810134.CrossRefPubMedPubMedCentral
14.
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14(2): 113–23.
15.
Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT. Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45(16):2867–73.CrossRefPubMed
16.
Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, Gong G, Li G. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomark Prev. 2013;22(8):1395–408.CrossRef
17.
Wada T, Kunisaki C, Ono HA, Makino H, Akiyama H, Endo I. Implications of BMI for the prognosis of gastric cancer among the Japanese population. Dig Surg. 2015;32(6):480–6.CrossRefPubMed
18.
Liu BZ, Tao L, Chen YZ, Li XZ, Dong YL, Ma YJ, Li SG, Li F, Zhang WJ. Preoperative body mass index, blood albumin and triglycerides predict survival for patients with gastric cancer. PLoS One. 2016;11(6):e0157401.CrossRefPubMedPubMedCentral
19.
Hirao M, Tsujinaka T, Imamura H, Kurokawa Y, Inoue K, Kimura Y, Shimokawa T, Furukawa H. Osaka gastrointestinal cancer chemotherapy study group (OGSG). Overweight is a risk factor for surgical site infection following distal gastrectomy for gastric cancer. Gastric Cancer. 2013;16(2):239–44.CrossRefPubMed
20.
Kim MG, Yook JH, Kim KC, Kim TH, Kim HS, Kim BS, Kim BS. Influence of obesity on early surgical outcomes of laparoscopic-assisted gastrectomy in gastric cancer. Surg Laparosc Endosc Percutan Tech. 2011;21(3):151–4.CrossRefPubMed
21.
Struecker B, Biebl M, Dadras M, Chopra S, Denecke C, Spenke J, Heilmann AC, Bahra M, Sauer IM, Pratschke J, et al. The impact of obesity on outcomes following resection for gastric cancer. Dig Surg. 2017;34(2):133–41.CrossRefPubMed
22.
Kulig J, Sierzega M, Kolodziejczyk P, Dadan J, Drews M, Fraczek M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G, et al. Implications of overweight in gastric cancer: a multicenter study in a western patient population. Eur J Surg Oncol. 2010;36(10):969–76.CrossRefPubMed
23.
Wang Z, Zhang X, Liang J, Hu J, Zeng W, Zhou Z. Short-term outcomes for laparoscopy-assisted distal gastrectomy for body mass index ≥30 patients with gastric cancer. J Surg Res. 2015;195(1):83–8.CrossRefPubMed
24.
Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Effect of body mass index in patients undergoing resection for gastric cancer: a single center US experience. J Gastrointest Surg. 2014;18(3):505–11.CrossRefPubMed
25.
Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763–78.CrossRefPubMed
26.
Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamaguchi T, Nakajima T. Better 5-year survival rate following curative gastrectomy in overweight patients. Ann Surg Oncol. 2009;16(12):3245–51.CrossRefPubMed
27.
Lin YS, Huang KH, Lan YT, Fang WL, Chen JH, Lo SS, Hsieh MC, Li AF, Chiou SH, Wu CW. Impact of body mass index on postoperative outcome of advanced gastric cancer after curative surgery. J Gastrointest Surg. 2013;17(8):1382–91.CrossRefPubMed
28.
Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005;5(11):844–52.CrossRefPubMed
Metadata
Title
Impact of body mass index on surgical outcomes of gastric cancer
Authors
Fan Feng
Gaozan Zheng
Xiaohua Guo
Zhen Liu
Guanghui Xu
Fei Wang
Qiao Wang
Man Guo
Xiao Lian
Hongwei Zhang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4063-9

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Research article

Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients

Research article

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

Research article

Association between age factors and strategies for promoting participation in gastric and colorectal cancer screenings

Research article

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study

Research article

Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits